| Identification | Back Directory | [Name]
2-Oxa-5-azabicyclo[2.2.1]heptane, 5-[2-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-6-[6-(4-methoxy-3-pyridinyl)-4-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl]-1-methyl-1H-imidazo[4,5-c]pyridin-4-yl]-, (1R,4R)- | [CAS]
2769715-68-4 | [Synonyms]
BI-4732
2-Oxa-5-azabicyclo[2.2.1]heptane, 5-[2-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-6-[6-(4-methoxy-3-pyridinyl)-4-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl]-1-methyl-1H-imidazo[4,5-c]pyridin-4-yl]-, (1R,4R)- | [Molecular Formula]
C32H36N10O2 | [MOL File]
2769715-68-4.mol | [Molecular Weight]
592.7 |
| Chemical Properties | Back Directory | [density ]
1.56±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
9.16±0.30(predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
BI-4732 a potent inhibitor EGFR-activating (E19del and L858R) and T790M mutations, with high blood-brian barrier penetration, targeting a broad range of EGFR mutations, including C797S. BI-4732 has anti-tumor activity[1]. | [References]
[1] Eun Ji Lee, et al. Discovery of a novel potent EGFR inhibitor against EGFR activating mutations and on-target resistance in NSCLC. Clin Cancer Res. 2024 Feb 8. DOI:10.1158/1078-0432.CCR-23-2951 |
|
|